Related references
Note: Only part of the references are listed.Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
Andreas Becker et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan
Wataru Munakata et al.
CANCER SCIENCE (2019)
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
Jennifer Series et al.
HAEMATOLOGICA (2019)
Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis
Shyi-Jou Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
Viola Denzinger et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA
Christine Radawski et al.
RHEUMATOLOGY AND THERAPY (2019)
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
Ann E. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
Jun Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy
Melanie C. Dispenza et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C. Byrd et al.
Oncotarget (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis
Samantha A. Chalmers et al.
CLINICAL IMMUNOLOGY (2018)
Lupus Nephritis: Current Treatment Paradigm and Unmet Needs
Steven P. Menez et al.
REVIEWS ON RECENT CLINICAL TRIALS (2018)
Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
Jyoti Bakshi et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus
Samantha A. Chalmers et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Viralkumar Patel et al.
CLINICAL CANCER RESEARCH (2017)
Update on Lupus Nephritis
Salem Almaani et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
Sun Ku Lee et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
Phu N. Tran et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions
Melanie C. Dispenza et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity
Jennifer A. Regan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
Kathleen M. Gillooly et al.
PLOS ONE (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
Hong Wu et al.
SCIENTIFIC REPORTS (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils
D. Smiljkovic et al.
ALLERGY (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus
Yu-Yon Kim et al.
ARTHRITIS RESEARCH & THERAPY (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Peter Norman
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase
Samantha A. Chalmers et al.
SCIENTIFIC REPORTS (2016)
BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells
David J. Lamb et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
The pathogenesis, diagnosis and treatment of lupus nephritis
Noa Schwartz et al.
CURRENT OPINION IN RHEUMATOLOGY (2014)
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
S. E. M. Herman et al.
LEUKEMIA (2014)
Suppression of Glomerulonephritis in Lupus-Prone NZB x NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase
Paola Mina-Osorio et al.
ARTHRITIS AND RHEUMATISM (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica K. Evans et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Bevra H. Hahn et al.
ARTHRITIS CARE & RESEARCH (2012)
MECHANISMS OF DISEASE Systemic Lupus Erythematosus
George C. Tsokos
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Mary Ellen Conley et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Dual functions of Bruton's tyrosine kinase and tec kinase during Fcγ receptor-induced signaling and phagocytosis
Jenny Jongstra-Bilen et al.
JOURNAL OF IMMUNOLOGY (2008)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Modulation of the Fc epsilon receptor I signaling by tyrosine kinase inhibitors: Search for therapeutic targets of inflammatory and allergy diseases
P Luskova et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
EA Leadbetter et al.
NATURE (2002)
Share Paper
